Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Urovaxom to prevent postoperative febrile urinary tract infection after ureteroscopic ureterolithotomy in patients with prior urinary tract infection
KCT0006991Phase 4Recruiting
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of OM-89 in urinary tract infection (UTI), sponsored by AJU PHARM Co., Ltd.. Started Jan 2022; status: recruiting.
02
Drugs
OM-89
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on KCT0006991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006991.